Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of 1 of the following:~  * Myelodysplastic syndromes (MDS)~    * International Prognostic Scoring System (IPSS) score ≥ intermediate-2~ * Chronic myelomonocytic leukemia~ * Acute myeloid leukemia arising from MDS~* Must have failed or are ineligible for or intolerant to treatment with azacitidine~  * Patients with normal marrow cytogenetics or an isolated 5q- abnormality must have failed or are ineligible for or intolerant to treatment with lenalidomide~ * Patients who are HLA-DR15-positive must have failed or are ineligible for pharmacologic immunosuppression (e.g., anti-thymocyte globulin, cyclosporine, steroids)~* No presence of cytotoxic antibodies against donor lymphocytes~* No HLA-identical donor available OR ineligible for HLA-identical allogeneic bone marrow transplantation~* HLA partially mismatched (haploidentical) related donor available~  * First-degree related donor, including half-siblings or first cousins~ * Inherited recombinant haplotype from parents allowed if donor shares ≥ 1 HLA antigen at each of the HLA-A, -B, and DR loci~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100%~* Bilirubin \< 3.0 mg/dL~* AST and ALT ≤ 4 times upper limit of normal~* Creatinine \< 3.0 mg/dL~* LVEF \> 35%~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* No prior transfusions from donor~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide + T cells (Type: EXPERIMENTAL): Conditioning regimen with cyclophosphamide followed by donor T cells on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).